peginterferon alfa 2a (Pegasys)

From Aaushi
Jump to navigation Jump to search

Introduction

Polyethylene-glycol modified interferon alfa 2a.

Tradename: Pegasys

Indications

Dosage

Pharmacokinetics

Monitor

Adverse effects

Laboratory

More general terms

Additional terms

Components

References

  1. Journal Watch 21(2):14, 2001 Zeuzem et al N Engl J Med 343:1666, 2000 Heathcote et al N Engl J Med 343:1673, 2000
  2. 2.0 2.1 2.2 Journal Watch 24(21):162-63, 2004 Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N; Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004 Sep 16;351(12):1206-17. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15371578
  3. Department of Veterans Affairs, VA National Formulary
  4. 4.0 4.1 Ghany MG et al AASLD PRACTICE GUIDELINES Diagnosis, Management, and Treatment of Hepatitis C: An Update American Association for the Study Liver Diseases (AASLD) 2009, Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.22759 http://www.aasld.org/practiceguidelines/Documents/AASLD_PG--diagnosis_of_HEP_C_2009.pdf
  5. 5.0 5.1 Prescriber's Letter 17(7): 2010 Recommended Lab Monitoring for Common Medications Liver Function Test Scheduling Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260704&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 Schaefer M et al Escitalopram for the Prevention of Peginterferon- alpha-2a-Associated Depression in Hepatitis C Virus- Infected Patients Without Previous Psychiatric Disease: A Randomized Trial. Annals of Internal Medicine, July 17, 2012 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22801672 <Internet> http://annals.org/article.aspx?articleid=1216554
  7. 7.0 7.1 7.2 7.3 Medical Knowledge Self Assessment Program (MKSAP) 16 American College of Physicians, Philadelphia 2012
  8. 8.0 8.1 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline information for boceprevir, peginterferon alfa-2a, peginterferon alfa-2b, ribavirin, telaprevir and IFNL3. https://www.pharmgkb.org/guideline/PA166110235